STOCK TITAN

Kiniksa’s John F. Paolini exercises 44,126 options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc reports that chief medical officer John F. Paolini exercised options on November 13, 2026, acquiring 44,126 Class A ordinary shares. Exercise prices were $10.36 for 29,670 options, $11.10 for 4,994, $11.97 for 3,723, $12.97 for 3,144, and $15.52 for 2,595.

Insider Paolini John F.
Role CHIEF MEDICAL OFFICER
Type Security Shares Price Value
Exercise Share Option F1 29,670 $0.00 $0.00
Exercise Share Option F1 4,994 $0.00 $0.00
Exercise Share Option F1 3,723 $0.00 $0.00
Exercise Share Option F1 3,144 $0.00 $0.00
Exercise Share Option F1 2,595 $0.00 $0.00
Exercise Class A Ordinary Share 29,670 $10.36 $307K
Exercise Class A Ordinary Share 4,994 $11.10 $55K
Exercise Class A Ordinary Share 3,723 $11.97 $45K
Exercise Class A Ordinary Share 3,144 $12.97 $41K
Exercise Class A Ordinary Share 2,595 $15.52 $40K
Holdings After Transaction: Share Option — 196,804 options (Direct); Class A Ordinary Share — 114,048 shares (Direct)
Footnotes (1)
  1. F1. The option is fully vested and exercisable.
Options exercised 44,126 options Five exercises dated November 13, 2026
Option exercise tranche 29,670 options; $10.36 per share Dated November 13, 2026; expiration February 29, 2028
Option exercise tranche 4,994 options; $11.10 per share Dated November 13, 2026; expiration April 6, 2032
Option exercise tranche 3,723 options; $11.97 per share Dated November 13, 2026; expiration August 31, 2032
Option exercise tranche 3,144 options; $12.97 per share Dated November 13, 2026; expiration September 1, 2031
Option exercise tranche 2,595 options; $15.52 per share Dated November 13, 2026; expiration March 12, 2030
Share Option technical
"Share Option exercised on November 13, 2026"
Class A Ordinary Share technical
"underlying security: Class A Ordinary Share"
A Class A ordinary share is a type of common stock a company issues that carries a specific set of rights—most often particular voting power, dividend terms, or transfer rules—distinct from other share classes. For investors it matters because those rights affect control over company decisions, how income is paid out, and how easy shares are to buy or sell; think of it like a tiered ticket that gives different access and influence at the same event.
fully vested and exercisable technical
"The option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KNSA shares did John F. Paolini acquire through option exercises?

John F. Paolini, Kiniksa’s chief medical officer, reported exercising options for 44,126 Class A ordinary shares on November 13, 2026. The five option tranches had exercise prices of $10.36, $11.10, $11.97, $12.97 and $15.52 per share.

When did John F. Paolini’s KNSA options expire?

The reported option tranches had expiration dates of February 29, 2028; April 6, 2032; August 31, 2032; September 1, 2031; and March 12, 2030, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Paolini John F.

(Last)(First)(Middle)
C/O KINIKSA PHARMACEUTICALS INT'L
105 PICCADILLY, SECOND FLOOR

(Street)
LONDONW1J 7NJ

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF MEDICAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Ordinary Share11/13/2026M29,670A$10.3699,592D
Class A Ordinary Share11/13/2026M4,994A$11.1104,586D
Class A Ordinary Share11/13/2026M3,723A$11.97108,309D
Class A Ordinary Share11/13/2026M3,144A$12.97111,453D
Class A Ordinary Share11/13/2026M2,595A$15.52114,048D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option$10.3611/13/2026M29,670 (1)02/29/2028Class A Ordinary Share29,670$00D
Share Option$11.111/13/2026M4,994 (1)04/06/2032Class A Ordinary Share4,994$054,936D
Share Option$11.9711/13/2026M3,723 (1)08/31/2032Class A Ordinary Share3,723$056,207D
Share Option$12.9711/13/2026M3,144 (1)09/01/2031Class A Ordinary Share3,144$038,256D
Share Option$15.5211/13/2026M2,595 (1)03/12/2030Class A Ordinary Share2,595$047,405D
Explanation of Responses:
1. The option is fully vested and exercisable.
/s/ Douglas Barry, Attorney-in-Fact11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading